MAP2K7 and non-small cell lung carcinoma: More importantly, upregulation of miR-31 in NSCLC may regulate RAF-MEK-ERK and PI3K-AKT signaling pathways by directly targeting RASA1 and FIH-1, and thus contributing to the acquired gefitinib resistance.